Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer

NCT00785226 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00785226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00785226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer
Lead sponsor
Bayer
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2008
Completion date
April 30, 2012
Enrollment
62 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer